Belantamab mafodotin with pomalidomide and dexamethasone for previously treated relapsed/refractory multiple myeloma

Belantamab mafodotin in combination with pomalidomide and dexamethasone is in clinical development for the treatment of relapsed and refractory multiple myeloma (MM) in adult patients who have previously received at least one prior MM therapy. MM is a rare form of cancer characterised by excessive production of abnormal, immature cells (plasma cells) found in the bone marrow. MM is a debilitating and life-threatening disease particularly because it disrupts the normal functioning of the bone marrow, damages the bones and causes kidney failure. Refractory MM is a significant clinical challenge with poor outcomes for patients whose disease has become resistant to the current standard of care. There is therefore need for more treatment options.